Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.53 +1.71%

+$0.29 today

Market cap
$1.56B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 1.86M

Average 3.08M

SRPT Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $210.47M (cash outflow) rose 260.8% year over year, ahead of the -42.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -10.9% a year.

Context

  • Accounts payables amounted to 4.7% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +260.8% holds above the trailing-twelve-month pace of -42.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$210.47M-184.3% QoQ
Last fiscal yearDec 2025
$104.27M-5.8% YoY
LTMMar 2026
$39.15M-42.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+260.8%——
1 year-5.8%——
3-year CAGR-10.9%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
104.27M USD
Year-over-year change
-5.8%
4-year CAGR
+45.5%

Accounts Payables vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's LTM Mar 2026 accounts payables of $39.15M is the 2nd largest of the 11 companies compared; the peer median is $1.93M.
  • Its year-over-year change of -42.1% is the 5th highest of 10, against a peer median of -66.8%.
  • Accounts payables amounts to 1.8% of revenue for SRPT, versus a peer median of 1.4%.
SRPT Competitors Peer median
Accounts Payables for SRPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$65.76M -237.3%-26.8%1.4%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$39.15M -42.1%-10.9%1.8%
DYNDyne Therapeutics, Inc.LTM Jun 2026$23.17M +98.6%——
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$11.71M -66.8%—1.2%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$6.44M +1108.8%—9.7%
WVEWave Life Sciences Ltd.LTM Mar 2026$4.81M +99.3%—6.7%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$2.28M +126.9%-5.9%—
PEPGPepGen Inc.LTM Mar 2026$2.06M -230.7%-12.7%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.59M -99.4%+70.5%—
SLDBSolid Biosciences Inc.LTM Mar 2026$767K -76.5%-40.7%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding SRPT) $1.93M-66.8%-12.7%1.4%

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
Deferred Income Tax15.81M0000
Stock-Based Compensation113.94M233.02M182.51M184.3M123.4M
Change in Working Capital(98.17M)(39.47M)(481.09M)(716.61M)78.04M
Accounts Receivables(51.65M)(61.64M)(185.7M)(201.66M)203.76M
Inventory(83.77M)(50.78M)(147.71M)(395.17M)(301.09M)
Accounts Payables23.3M147.57M(50.14M)110.65M104.27M
Other Working Capital13.96M(74.62M)(97.54M)(230.42M)71.11M
Other Non-Cash Items(94M)142.73M289.16M53.56M261.98M
Operating Cash Flow(443.17M)(325.35M)(500.99M)(205.79M)(205.48M)
Capital Expenditures(38.49M)(32.25M)(87.35M)(146.96M)(101.97M)
Acquisitions (Net)00000
Purchases of Investments(29.99M)(1.94B)(2.05B)(1.1B)(44.66M)
Sales of Investments466M923.22M1.87B2B469.97M
Other Investing Activities97.89M(1.43M)90.76M(10M)(253.7M)
Investing Cash Flow495.41M(1.05B)(165.8M)755.56M69.64M
Debt Repayment0304.17M0(68K)(162.59M)
Common Stock Issued548.53M00036.32M
Common Stock Repurchased0000(25.01M)
Dividends Paid00000
Other Financing Activities13.04M(71.66M)125M124.87M(17.06M)
Financing Cash Flow561.57M232.51M125M124.81M(168.34M)
Effect of Forex Changes00000
Net Change in Cash613.81M(1.14B)(541.79M)674.58M(304.18M)
Free Cash Flow(481.66M)(357.6M)(588.34M)(352.74M)(307.45M)

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.